ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. This annual meeting is one of the largest oncology conferences there is and will bring together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
We hope to see you there and set up a meeting with one of our oncology scientific leaders to discuss how we can further streamline your clinical trial!
As the Chief Commercial Officer, Michael leads the US, Europe, and APAC business development teams, along with proposal and contracting groups. He brings over 30 years of business development and life sciences experience with companies including Cardinal Health, PPD, ICON, and, most recently, Ergomed/PrimeVigilance. Over the last 16+ years, Michael has led various CRO commercial teams including those in business development and global strategic accounts driving business strategy for large pharma and biotech companies. He also has a strong background in supporting strategic partnerships, proposal development, inside sales, and sales training and development.
Dr. VanderWalde specializes in melanoma and is experienced in genomic tumor assessment, public health, tumor immunotherapy, medical ethics and precision oncology. He is the Global Head of Clinical Research at Caris Life Sciences and works as Research Faculty at West Cancer Center where he served as the Director of Research from 2014 to 2021. He is also Professor in the Division of Epidemiology at the University of Memphis School of Public Health. Dr. VanderWalde has extensive experience in clinical research, including the design and conduct of clinical trials, results reporting, regulatory filing and interactions between investigators and the pharmaceutical industry.
McCormick Place
2301 S King Dr
Chicago, IL
USA
Meet with George Clinical! Contact us to schedule a time now.